Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST

 

 Buy Article Permissions and Reprints

Abstract

Recent advancements have improved the management of patients with liver cancer. Results of studies have informed how to stage and decide the optimal treatment option for each patient with an adequate balance between risks and benefits. The Barcelona Clinic Liver Cancer (BCLC) staging and treatment strategy has been widely endorsed for this purpose. This is not a rigid system: One of the key aspects in the management of patients is the optimal timing for systemic treatment initiation and for declaring tumor progression and/or treatment failure. Some patients at intermediate or even early stage may be considered for systemic therapy as options of higher priority may have failed or may not be feasible. Sorafenib is the sole systemic agent that has shown efficacy in phase 3 trials. Other agents (sunitinib, brivanib, linifanib, everolimus, ramucirumab) have failed in terms of safety and/or survival benefit. Optimal sorafenib administration and adequate adherence of the patients are crucial requirements to obtain the benefits of the drug. Because development of adverse events has been shown to correlate with better outcome, careful dose adjustments should be in place while avoiding unnecessary treatment interruption. Furthermore, recent studies have shown that progression at imaging may not translate in poor prognosis and that treatment beyond progression may be considered if there is no option for a second-line research trial.

In this review, the authors examine all of the controversial aspects that affect treatment initiation and maintenance, how response to treatment should be evaluated, and define the needs that are faced by current research.

• References

• 1 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379 (9822) 1245-1255
  CrossrefPubMedGoogle Scholar
• 2 Bruix J, Sherman M ; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (3) 1020-1022
  CrossrefPubMedGoogle Scholar
• 3 European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 (4) 908-943
  CrossrefPubMedGoogle Scholar
• 4 Verslype C, Rosmorduc O, Rougier P ; ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl. 07) vii41-vii48
  CrossrefPubMedGoogle Scholar
• 5 Sørensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 1993; 67 (4) 773-775
  CrossrefPubMedGoogle Scholar
• 6 Bruix J, Reig M, Rimola J , et al. Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology 2011; 54 (6) 2238-2244
  CrossrefPubMedGoogle Scholar
• 7 Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60 (8) 646-649
  CrossrefPubMedGoogle Scholar
• 8 Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014; 383 (9930) 1749-1761
  CrossrefPubMedGoogle Scholar
• 9 Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31 (4) 864-871
  CrossrefPubMedGoogle Scholar
• 10 Fede G, D'Amico G, Arvaniti V , et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol 2012; 56 (4) 810-818
  CrossrefPubMedGoogle Scholar
• 11 Wong F, O'Leary JG, Reddy KR , et al; North American Consortium for Study of End-Stage Liver Disease. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology 2013; 145 (6) 1280-1288 , e1
  CrossrefPubMedGoogle Scholar
• 12 Martin P, DiMartini A, Feng S, Brown Jr R, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014; 59 (3) 1144-1165
  CrossrefPubMedGoogle Scholar
• 13 Barreto R, Fagundes C, Guevara M , et al. Type-1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival. Hepatology 2014; 59 (4) 1505-1513
  CrossrefPubMedGoogle Scholar
• 14 Raoul JL, Sangro B, Forner A , et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37 (3) 212-220
  CrossrefPubMedGoogle Scholar
• 15 Reig M, Rimola J, Torres F , et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology 2013; 58 (6) 2023-2031
  CrossrefPubMedGoogle Scholar
• 16 Sieghart W, Hucke F, Pinter M , et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 2013; 57 (6) 2261-2273
  CrossrefPubMedGoogle Scholar
• 17 Bruix J, Sherman M ; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42 (5) 1208-1236
  CrossrefPubMedGoogle Scholar
• 18 Castells A, Bruix J, Brú C , et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995; 109 (3) 917-922
  CrossrefPubMedGoogle Scholar
• 19 Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. Hepatology 2004; 40 (6) 1361-1369
  CrossrefPubMedGoogle Scholar
• 20 Llovet JM, Sala M, Castells L , et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000; 31 (1) 54-58
  CrossrefPubMedGoogle Scholar
• 21 Beaugrand M, Sala M, Degos F. Treatment of advanced hepatocellular carcinoma by seocalcitol (a vit D analogue): an international randomized double-blind placebo-controlled study in 747 patients. J Hepatol 2005; 42: 17A
  PubMedGoogle Scholar
• 22 Llovet JM, Ricci S, Mazzaferro V , et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (4) 378-390
  CrossrefPubMedGoogle Scholar
• 23 Cheng AL, Kang YK, Chen Z , et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10 (1) 25-34
  CrossrefPubMedGoogle Scholar
• 24 Abou-Alfa GK, Schwartz L, Ricci S , et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24 (26) 4293-4300
  CrossrefPubMedGoogle Scholar
• 25 Therasse P, Arbuck SG, Eisenhauer EA , et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92 (3) 205-216
  CrossrefPubMedGoogle Scholar
• 26 Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010; 51 (4) 1274-1283
  CrossrefPubMedGoogle Scholar
• 27 Llovet JM, Bustamante J, Castells A , et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29 (1) 62-67
  CrossrefPubMedGoogle Scholar
• 28 Llovet JM, Di Bisceglie AM, Bruix J , et al; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100 (10) 698-711
  CrossrefPubMedGoogle Scholar
• 29 Raoul JL, Bruix J, Greten TF , et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol 2012; 56 (5) 1080-1088
  CrossrefPubMedGoogle Scholar
• 30 Bruix J, Raoul JL, Sherman M , et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012; 57 (4) 821-829
  CrossrefPubMedGoogle Scholar
• 31 Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J ; SHARP Investigators Study Group. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18 (8) 2290-2300
  CrossrefPubMedGoogle Scholar
• 32 Reig M, Torres F, Rodriguez-Lope C , et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol 2014; 61 (2) 318-324
  CrossrefPubMedGoogle Scholar
• 33 Finn RS. Drug therapy: sorafenib. Hepatology 2010; 51 (5) 1843-1849
  CrossrefPubMedGoogle Scholar
• 34 Iavarone M, Cabibbo G, Piscaglia F , et al; SOFIA (SOraFenib Italian Assessment) study group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011; 54 (6) 2055-2063
  CrossrefPubMedGoogle Scholar
• 35 Abou-Alfa GK. Sorafenib use in hepatocellular carcinoma: more questions than answers. Hepatology 2014; 60 (1) 15-18
  CrossrefPubMedGoogle Scholar
• 36 Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011; 8 (5) 292-301
  CrossrefPubMedGoogle Scholar
• 37 Oxnard GR, Morris MJ, Hodi FS , et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst 2012; 104 (20) 1534-1541
  CrossrefPubMedGoogle Scholar
• 38 Wilhelm SM, Carter C, Tang L , et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64 (19) 7099-7109
  CrossrefPubMedGoogle Scholar
• 39 Cheng AL, Kang YK, Lin DY , et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013; 31 (32) 4067-4075
  CrossrefPubMedGoogle Scholar
• 40 Johnson PJ, Qin S, Park JW , et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013; 31 (28) 3517-3524
  CrossrefPubMedGoogle Scholar
• 41 Cainap C, Qin S, Huang W-T , et al. Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2013; 31 (Suppl. 04) 249
  PubMedGoogle Scholar
• 42 Zhu A, Rosmorduc O, Evans J , et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). Ann Oncol 2012; 23: LBA2
  PubMedGoogle Scholar
• 43 Llovet JM, Decaens T, Raoul JL , et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013; 31 (28) 3509-3516
  CrossrefPubMedGoogle Scholar
• 44 Zhu AX, Kudo M, Assenat E , et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 2014; 312 (1) 57-67
  CrossrefPubMedGoogle Scholar
• 45 Zhu et al. Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: Results from the randomized phase III REACH study. ESMO 2014. LBA16. Ann Oncol 2014; 25 (Suppl. 04)
  PubMedGoogle Scholar
• 46 Santoro A, Rimassa L, Borbath I , et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013; 14 (1) 55-63
  CrossrefPubMedGoogle Scholar
• 47 Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature 2013; 501 (7467) 355-364
  CrossrefPubMedGoogle Scholar
• 48 Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014; 63 (5) 844-855
  CrossrefPubMedGoogle Scholar
• 49 Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol 2014; 11 (3) 129-144
  CrossrefPubMedGoogle Scholar
• 50 Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013; 10 (8) 472-484
  CrossrefPubMedGoogle Scholar
• 51 Moertel CG, Hanley JA. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 1976; 38 (1) 388-394
  CrossrefPubMedGoogle Scholar
• 52 World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organization; 1979
  Google Scholar
• 53 Eisenhauer EA, Therasse P, Bogaerts J , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (2) 228-247
  CrossrefPubMedGoogle Scholar
• 54 Bruix J, Sherman M, Llovet JM , et al; EASL Panel of Experts on HCC; European Association for the Study of the Liver. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35 (3) 421-430
  CrossrefPubMedGoogle Scholar
• 55 Riaz A, Miller FH, Kulik LM , et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 2010; 303 (11) 1062-1069
  CrossrefPubMedGoogle Scholar
• 56 Lencioni R, Llovet JM, Han G , et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. J Clin Oncol 2012; 30 (Suppl. 04) abstract LBA154
  PubMedGoogle Scholar
• 57 Kudo M, Imanaka K, Chida N , et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; 47 (14) 2117-2127
  CrossrefPubMedGoogle Scholar
• 58 Choi H, Charnsangavej C, Faria SC , et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25 (13) 1753-1759
  CrossrefPubMedGoogle Scholar
• 59 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30 (1) 52-60
  Article in Thieme ConnectPubMedGoogle Scholar
• 60 Kudo M, Kubo S, Takayasu K , et al; Liver Cancer Study Group of Japan (Committee for Response Evaluation Criteria in Cancer of the Liver, Liver Cancer Study Group of Japan). Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). Hepatol Res 2010; 40 (7) 686-692
  CrossrefPubMedGoogle Scholar
• 61 Wolchok JD, Hoos A, O'Day S , et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15 (23) 7412-7420
  CrossrefPubMedGoogle Scholar
• 62 Berzigotti A, García-Criado A, Darnell A, García-Pagán JC. Imaging in clinical decision-making for portal vein thrombosis. Nat Rev Gastroenterol Hepatol 2014; 11 (5) 308-316
  CrossrefPubMedGoogle Scholar
• 63 Vilana R, Bru C, Bruix J, Castells A, Sole M, Rodes J. Fine-needle aspiration biopsy of portal vein thrombus: value in detecting malignant thrombosis. AJR Am J Roentgenol 1993; 160 (6) 1285-1287
  CrossrefPubMedGoogle Scholar
• 64 Heo J, Reid T, Ruo L , et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013; 19 (3) 329-336
  CrossrefPubMedGoogle Scholar
• 65 Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6 (10) 715-727
  CrossrefPubMedGoogle Scholar
• 66 Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know. Nat Rev Clin Oncol 2011; 8 (10) 577-585
  CrossrefPubMedGoogle Scholar
• 67 Yeo W, Chung HC, Chan SL , et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol 2012; 30 (27) 3361-3367
  CrossrefPubMedGoogle Scholar
• 68 Straussman R, Morikawa T, Shee K , et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487 (7408) 500-504
  CrossrefPubMedGoogle Scholar
• 69 Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141 (1) 39-51
  CrossrefPubMedGoogle Scholar
• 70 Wilson TR, Fridlyand J, Yan Y , et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487 (7408) 505-509
  CrossrefPubMedGoogle Scholar
• 71 Thomas MB, Chadha R, Glover K , et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007; 110 (5) 1059-1067
  CrossrefPubMedGoogle Scholar
• 72 Philip PA, Mahoney MR, Allmer C , et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005; 23 (27) 6657-6663
  CrossrefPubMedGoogle Scholar
• 73 Toh HC, Chen PJ, Carr BI , et al. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer 2013; 119 (2) 380-387
  CrossrefPubMedGoogle Scholar
• 74 Barone C, Basso M, Biolato M , et al. A phase II study of sunitinib in advanced hepatocellular carcinoma. Dig Liver Dis 2013; 45 (8) 692-698
  CrossrefPubMedGoogle Scholar
• 75 Koeberle D, Montemurro M, Samaras P , et al. Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 2010; 15 (3) 285-292
  CrossrefPubMedGoogle Scholar
• 76 Zhu AX, Sahani DV, Duda DG , et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009; 27 (18) 3027-3035
  CrossrefPubMedGoogle Scholar
• 77 Faivre S, Raymond E, Boucher E , et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009; 10 (8) 794-800
  CrossrefPubMedGoogle Scholar
• 78 Park JW, Finn RS, Kim JS , et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011; 17 (7) 1973-1983
  CrossrefPubMedGoogle Scholar
• 79 Qin SK, Cao MR, Qian J , et al. Clinical study of FOLFOX regimen for the patients with advanced hepatocellular carcinoma [in Chinese]. Chin Clin Oncol 2005; 10: 58-60
  PubMedGoogle Scholar
• 80 Qin S, Bai Y, Lim HY , et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 2013; 31 (28) 3501-3508
  CrossrefPubMedGoogle Scholar
• 81 Finn RS, Kang YK, Mulcahy M , et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18 (7) 2090-2098
  CrossrefPubMedGoogle Scholar